Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374).
Patients with heparin-induced platelet activation who are reexposed to heparin may have recurrent thrombocytopenia, intravascular thrombosis, arterial emboli, or sudden death. To permit carotid endarterectomy in two patients with confirmed heparin-induced platelet activation, we compared the efficacies of aspirin and iloprost, a stable analogue of prostacyclin, in preventing heparin-induced platelet activation. In the first patient, although aspirin prevented both in vitro heparin-induced platelet aggregation (70% without and 7.5% with aspirin) and 14C serotonin release (48% without and 0% with aspirin), intraoperative administration of heparin resulted in an increase in plasma levels of platelet factor 4 from 8 to 260 ng/ml and beta-thromboglobulin levels from 29 to 39 ng/ml. In addition, the circulating platelet count decreased from 221,000 to 174,000 microliters, and 15% spontaneous platelet aggregation was observed. Fortunately, fibrinopeptide A levels remained less than 10 ng/ml intraoperatively, and no thrombotic complications occurred. In the second patient, aspirin did not prevent heparin-induced platelet aggregation in vitro (65% without and 41% with aspirin); however, iloprost (0.01 mumol/L) prevented both in vitro heparin-induced platelet aggregation (59.5% without and 0.0% with iloprost) and 14C serotonin release (56.7% without and 0.0% with iloprost). Therefore, a continuous infusion of iloprost was begun before administration of heparin and was continued until 20 minutes after reversal of heparin with protamine. After intraoperative administration of heparin, plasma levels of platelet factor 4 increased from 19 to 200 ng/ml, and beta-thromboglobulin levels increased from 56 to 76 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002339:Carotid Arteries / Q000601:surgery*; D004341:Drug Evaluation; D004691:Endarterectomy; D011464:Epoprostenol / Q000627:therapeutic use*; D005344:Fibrinopeptide A / Q000032:analysis; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016285:Iloprost; D008297:Male; D010972:Platelet Activating Factor / Q000032:analysis; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000032:analysis; D011300:Preoperative Care; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control; D001620:beta-Thromboglobulin / Q000032:analysis
D002317:Cardiovascular Agents; D010972:Platelet Activating Factor; D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D010978:Platelet Factor 4; D006493:Heparin; D011464:Epoprostenol; D016285:Iloprost; D001241:Aspirin